Cancer Research Consortium of West Michigan
P: 616.391.1230 | 800.336.6299 | www.crcwm.org



# FAST FACTS

## EAQ162CD - Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent

Eligibility Criteria for Patient Participants

1. Age ≥ 18 years.
2. Patients must have a life expectancy of ≥ 24 months
3. ECOG PS 0-3
4. Patients must have a newly diagnosed colon or rectal cancer or rectosigmoid junction (initial diagnosis, either a biopsy or curative surgery, whichever is most recent) within 60 days of registration and have either not yet received radiation or chemotherapy or are starting radiation or chemotherapy on the same day as registration.
5. Patients must have Stage I, II, or III disease at the time of enrollment and will be treated with curative-intent. This can be defined either clinically or pathologically if they have already undergone surgery. For staging of both colon and rectal cancer, the definition of stage I-III is based on the seventh edition (2010) or an updated version of the TNM staging system.
6. Patients are not eligible if they are already enrolled on a **treatment** clinical trial at the time of registration. They can remain on the study if they subsequently enroll on a treatment clinical trial during the study time period.
7. Patients are not eligible if they are to receive treatment at an outside facility throughout the duration of the trial.
8. Patients who choose to not receive radiation and/or chemotherapy after a curative-intent surgery are eligible to participate.
9. Patients with a history of previous malignancy (except non-melanoma skin or cervical in-situ cancer) treated (with either surgery, chemotherapy, and/or radiation) within the last 3 years are not eligible because it is possible that their employment and burden due to cancer care may be impacted by their previous malignancy and therefore add heterogeneity to the study.
10. Patients with two primary cancers that consist of colon, rectal or colorectal are not eligible.
11. Patients must be able to complete questionnaires in English.
12. Patients must sign and give written informed consent in accordance with institutional and federal guidelines

**Schema**


Colon or rectal cancer diagnosis Stage I, II, or III
60 days
REGISTRATION
Assessment 0: Baseline
Assessment 1: 3 months (+/- 4 weeks)
Assessment 2: 6 months (+/- 4 weeks)
Assessment 3: 12 months (+/- 4 weeks)
Assessment 4: 24 months (+/- 4 weeks)
Stratification Factors:
•Colon vs rectal cancer
•Chemotherapy vs no chemotherapy